Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:02:08.207Z.
Calculation as of: 2026-10-06T17:02:08.207Z.
Quote observation: 2026-10-06T17:00:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f97479f440d7a03605f533a56e26179237db48e588053495707f458dff3bcd44
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Erasca, Inc. (ERAS) | $5.07B | N/A | N/A | N/A | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.07B | N/A | 0.56 | 2.07 | 2.79 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.09B | N/A | N/A | N/A | N/A |
| Cogent Biosciences, Inc. (COGT)vs › | $5.18B | N/A | N/A | N/A | N/A |
| CRISPR Therapeutics AG (CRSP)vs › | $5.19B | N/A | N/A | N/A | N/A |
| Sotera Health Company (SHC)vs › | $5.26B | N/A | N/A | N/A | N/A |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.31B | N/A | N/A | N/A | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.84B | N/A | N/A | N/A | N/A |
| Doximity, Inc. (DOCS)vs › | $5.32B | 0.64 | 0.43 | 0.41 | 0.41 |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.81B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
